IPP Bureau

Lupin launches Bumetanide Injection USP in US
Lupin launches Bumetanide Injection USP in US

By IPP Bureau - November 20, 2024

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US

Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records
Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records

By IPP Bureau - November 20, 2024

Indegene announces new Center in Hyderabad
Indegene announces new Center in Hyderabad

By IPP Bureau - November 20, 2024

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies

CPHI India reports surge in exhibitor numbers
CPHI India reports surge in exhibitor numbers

By IPP Bureau - November 20, 2024

Modernization and supply chain diversity drive new growth

DKSH and Abcam join forces to advance life science research in Vietnam
DKSH and Abcam join forces to advance life science research in Vietnam

By IPP Bureau - November 19, 2024

This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

By IPP Bureau - November 19, 2024

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

By IPP Bureau - November 19, 2024

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years

Sanofi invests €40 million to strengthen antibody bioproduction in France
Sanofi invests €40 million to strengthen antibody bioproduction in France

By IPP Bureau - November 19, 2024

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

By IPP Bureau - November 19, 2024

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex

Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness
Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness

By IPP Bureau - November 17, 2024

Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

By IPP Bureau - November 16, 2024

EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24

Zota Health Care Q2 FY25 revenue up 48.6%
Zota Health Care Q2 FY25 revenue up 48.6%

By IPP Bureau - November 16, 2024

Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%

Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development
Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development

By IPP Bureau - November 16, 2024

He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University

Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications
Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications

By IPP Bureau - November 16, 2024

Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential

Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America
Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America

By IPP Bureau - November 16, 2024

Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions

Latest Stories

Interviews

Packaging